Literature DB >> 10714580

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.

N K Back, A van Wijk, D Remmerswaal, M van Monfort, M Nijhuis, R Schuurman, C A Boucher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10714580     DOI： 10.1097/00002030-200001070-00019

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  11 in total

Review 1.  Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Authors:  Mark A Boyd; Andrew M Hill
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.

Authors:  Geoffrey Mukwaya; Thomas MacGregor; David Hoelscher; Thomas Heming; Daniel Legg; Kelli Kavanaugh; Phillip Johnson; John P Sabo; Scott McCallister
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

Authors:  Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Kazuhiko Ide; Debananda Das; Yasuhiro Koh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

4.  Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Authors:  John D Baxter; Jonathan M Schapiro; Charles A B Boucher; Veronika M Kohlbrenner; David B Hall; Joseph R Scherer; Douglas L Mayers
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

Review 5.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

6.  Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

Authors:  Daniel Gonzalez de Requena; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

7.  Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.

Authors:  Linzhi Chen; John P Sabo; Elsy Philip; Yanping Mao; Stephen H Norris; Thomas R MacGregor; Jan M Wruck; Sandra Garfinkel; Mark Castles; Amy Brinkman; Hernan Valdez
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

Review 8.  Tipranavir.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.

Authors:  S Muzammil; A A Armstrong; L W Kang; A Jakalian; P R Bonneau; V Schmelmer; L M Amzel; E Freire
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

Review 10.  Tipranavir in the protease inhibitors arena.

Authors:  Barbara Vergani; Stefano Rusconi
Journal:  Drugs R D       Date:  2011-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.